Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. more
Time Frame | KZR | Sector | S&P500 |
---|---|---|---|
1-Week Return | -8.71% | -3.39% | -3.47% |
1-Month Return | -14.88% | -3.25% | -0.29% |
3-Month Return | 9.13% | -11.61% | 4.5% |
6-Month Return | -3.95% | -5.89% | 6.91% |
1-Year Return | -25.35% | 2.65% | 23.79% |
3-Year Return | -95.73% | 0.56% | 28.43% |
5-Year Return | -79.24% | 34.63% | 83.64% |
10-Year Return | -96.46% | 94.78% | 185.94% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | 7.00M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 1.30M | 1.54M | 1.51M | 1.02M | 1.07M | [{"date":"2019-12-31","value":84.26,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":97.8,"profit":true},{"date":"2022-12-31","value":66.26,"profit":true},{"date":"2023-12-31","value":69.04,"profit":true}] |
Gross Profit | (1.30M) | (1.54M) | (1.51M) | (1.02M) | 5.93M | [{"date":"2019-12-31","value":-21.92,"profit":false},{"date":"2020-12-31","value":-26.02,"profit":false},{"date":"2021-12-31","value":-25.45,"profit":false},{"date":"2022-12-31","value":-17.24,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | (Infinity%) | (Infinity%) | (Infinity%) | (Infinity%) | 84.77% | [{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Expenses | 37.34M | 42.95M | 54.66M | 71.16M | 118.42M | [{"date":"2019-12-31","value":31.53,"profit":true},{"date":"2020-12-31","value":36.27,"profit":true},{"date":"2021-12-31","value":46.16,"profit":true},{"date":"2022-12-31","value":60.09,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (37.34M) | (42.95M) | (54.66M) | (71.16M) | (105.24M) | [{"date":"2019-12-31","value":-3734200000,"profit":false},{"date":"2020-12-31","value":-4295000000,"profit":false},{"date":"2021-12-31","value":-5465900000,"profit":false},{"date":"2022-12-31","value":-7116200000,"profit":false},{"date":"2023-12-31","value":-10523700000,"profit":false}] |
Total Non-Operating Income/Expense | 4.51M | 2.42M | 58.00K | 5.85M | 12.45M | [{"date":"2019-12-31","value":36.24,"profit":true},{"date":"2020-12-31","value":19.41,"profit":true},{"date":"2021-12-31","value":0.47,"profit":true},{"date":"2022-12-31","value":46.97,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (35.09M) | (41.74M) | (54.63M) | (68.24M) | (101.87M) | [{"date":"2019-12-31","value":-3508700000,"profit":false},{"date":"2020-12-31","value":-4174200000,"profit":false},{"date":"2021-12-31","value":-5463000000,"profit":false},{"date":"2022-12-31","value":-6823900000,"profit":false},{"date":"2023-12-31","value":-10187000000,"profit":false}] |
Income Taxes | (3.56M) | (2.75M) | (1.35M) | (2.92M) | 898.11K | [{"date":"2019-12-31","value":-395.94,"profit":false},{"date":"2020-12-31","value":-306.42,"profit":false},{"date":"2021-12-31","value":-150.43,"profit":false},{"date":"2022-12-31","value":-325.46,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | (31.53M) | (38.99M) | (53.28M) | (65.32M) | (102.77M) | [{"date":"2019-12-31","value":-3153100000,"profit":false},{"date":"2020-12-31","value":-3899000000,"profit":false},{"date":"2021-12-31","value":-5327900000,"profit":false},{"date":"2022-12-31","value":-6531600000,"profit":false},{"date":"2023-12-31","value":-10276810500,"profit":false}] |
Income From Continuous Operations | (35.09M) | (41.74M) | (54.63M) | (68.24M) | (87.79M) | [{"date":"2019-12-31","value":-3508700000,"profit":false},{"date":"2020-12-31","value":-4174200000,"profit":false},{"date":"2021-12-31","value":-5463000000,"profit":false},{"date":"2022-12-31","value":-6823900000,"profit":false},{"date":"2023-12-31","value":-8779100000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (31.53M) | (38.99M) | (53.28M) | (65.32M) | (101.87M) | [{"date":"2019-12-31","value":-3153100000,"profit":false},{"date":"2020-12-31","value":-3899000000,"profit":false},{"date":"2021-12-31","value":-5327900000,"profit":false},{"date":"2022-12-31","value":-6531600000,"profit":false},{"date":"2023-12-31","value":-10187000000,"profit":false}] |
EPS (Diluted) | (1.84) | (0.97) | (1.03) | (1.01) | (1.41) | [{"date":"2019-12-31","value":-184,"profit":false},{"date":"2020-12-31","value":-97,"profit":false},{"date":"2021-12-31","value":-103,"profit":false},{"date":"2022-12-31","value":-101,"profit":false},{"date":"2023-12-31","value":-141,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
KZR | |
---|---|
Cash Ratio | 7.26 |
Current Ratio | 7.65 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
KZR | |
---|---|
ROA (LTM) | -28.07% |
ROE (LTM) | -51.48% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
KZR | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.18 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.82 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
KZR | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 6.56 |
P/B | 0.34 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | 0.06 |
Kezar Life Sciences Inc (KZR) share price today is $6.49
Yes, Indians can buy shares of Kezar Life Sciences Inc (KZR) on Vested. To buy Kezar Life Sciences Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in KZR stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Kezar Life Sciences Inc (KZR) via the Vested app. You can start investing in Kezar Life Sciences Inc (KZR) with a minimum investment of $1.
You can invest in shares of Kezar Life Sciences Inc (KZR) via Vested in three simple steps:
The 52-week high price of Kezar Life Sciences Inc (KZR) is $11.35. The 52-week low price of Kezar Life Sciences Inc (KZR) is $5.2.
The price-to-earnings (P/E) ratio of Kezar Life Sciences Inc (KZR) is
The price-to-book (P/B) ratio of Kezar Life Sciences Inc (KZR) is 0.34
The dividend yield of Kezar Life Sciences Inc (KZR) is 0.00%
The market capitalization of Kezar Life Sciences Inc (KZR) is $45.89M
The stock symbol (or ticker) of Kezar Life Sciences Inc is KZR